NEW YORK, Jan. 14 (GenomeWeb News) - Exagen Diagnostics has raised more than $5.4 million in a series A financing round, the company said today. Lead investor Tullis-Dickerson was joined by vSpring Capital and Wasatch Venture Fund.
Exagen, based in Albuquerque, N.M., uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.
The company was founded in 2002 as a spinoff from Quasar International. It has adapted a computational method used by Quasar to find defects in automotive parts to analyze large amounts of genomic data. Exagen plans to license its genomic marker sets to large diagnostic laboratories.